GT BIOPHARMA, INC. (GTBP) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -16.34M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 3.48M USD | Research and Development Expense |
| Selling, general and administration | 12.86M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-16.34M | (m) | (m) | $3.48M | $12.86M | (m) |
| 2026-03-31 | $-13.34M | (m) | (m) | $2.79M | $10.55M | (m) |
| 2025-12-31 | $-12.42M | (m) | (m) | $3.47M | $8.95M | (m) |
| 2025-09-30 | $-10.59M | (m) | (m) | $4.03M | $6.56M | (m) |
| 2025-06-30 | $-10.81M | (m) | (m) | $4.70M | $6.11M | (m) |
| 2025-03-31 | $-13.21M | (m) | (m) | $6.12M | $7.08M | (m) |
| 2024-12-31 | $-14.36M | (m) | (m) | $5.80M | $8.57M | (m) |
| 2024-09-30 | $-13.77M | (m) | (m) | $5.22M | $8.54M | (m) |
| 2024-06-30 | $-13.29M | (m) | (m) | $5.28M | $8.01M | (m) |
| 2024-03-31 | $-13.00M | (m) | (m) | $5.59M | $7.41M | (m) |
| 2023-12-31 | $-13.58M | (m) | (m) | $6.47M | $7.11M | (m) |
| 2023-09-30 | $-16.19M | (m) | (m) | $7.95M | $8.23M | (m) |
| 2023-06-30 | $-20.09M | (m) | (m) | $9.33M | $10.76M | (m) |
| 2023-03-31 | $-19.48M | (m) | (m) | $8.37M | $11.11M | (m) |
| 2022-12-31 | $-21.26M | (m) | (m) | $8.81M | $12.45M | (m) |
| 2022-09-30 | $-33.66M | (m) | (m) | $12.27M | $21.38M | (m) |
| 2022-06-30 | $-32.59M | (m) | (m) | $10.54M | $22.05M | (m) |
| 2022-03-31 | $-33.95M | (m) | (m) | $10.04M | $23.92M | (m) |
| 2021-12-31 | $-57.52M | (m) | (m) | $9.59M | $47.92M | (m) |
| 2021-09-30 | (m) | $0.00 | (m) | $3.52M | $38.01M | (m) |
| 2021-06-30 | (m) | $0.00 | (m) | $2.43M | $35.09M | (m) |
| 2021-03-31 | $34.70M | $0.00 | (m) | $1.80M | $32.90M | (m) |
| 2020-12-31 | $6.76M | $0.00 | (m) | $485.00K | $6.28M | (m) |
| 2020-09-30 | $-5.44M | (m) | (m) | $260.00K | $5.18M | (m) |
| 2020-06-30 | $-12.35M | (m) | (m) | $1.01M | $6.74M | (m) |
| 2020-03-31 | $-13.07M | (m) | (m) | $1.16M | $7.31M | (m) |
| 2019-12-31 | $-16.06M | (m) | (m) | $1.67M | $9.79M | (m) |
| 2019-09-30 | $-18.28M | (m) | (m) | $2.89M | $10.79M | (m) |
| 2019-06-30 | $-244.09M | (m) | (m) | $3.33M | $12.24M | (m) |
| 2019-03-31 | $-246.97M | (m) | (m) | $6.43M | $12.02M | (m) |
| 2018-12-31 | $-250.07M | (m) | (m) | $9.07M | $12.49M | (m) |
| 2018-09-30 | $-252.87M | (m) | (m) | $7.99M | $16.36M | (m) |
| 2018-06-30 | $-145.06M | $0.00 | $0.00 | $7.41M | $137.66M | (m) |
| 2018-03-31 | $-141.19M | $0.00 | $0.00 | $4.40M | $136.79M | (m) |
| 2017-12-31 | $-135.57M | $0.00 | $0.00 | $1.07M | $134.50M | (m) |
| 2017-09-30 | $-130.50M | $0.00 | $0.00 | $1.16M | $129.34M | (m) |
| 2017-06-30 | $-6.17M | $0.00 | $0.00 | $885.00K | $5.29M | (m) |
| 2017-03-31 | $-7.01M | $0.00 | $0.00 | $894.00K | $6.12M | (m) |
| 2016-12-31 | $-9.37M | $0.00 | $0.00 | $975.00K | $8.40M | (m) |
| 2016-09-30 | $-11.46M | $0.00 | $0.00 | $1.25M | $10.21M | (m) |
| 2016-06-30 | $-11.71M | $0.00 | $0.00 | $1.23M | $10.48M | (m) |
| 2016-03-31 | $-11.02M | $20.00K | $0.00 | $975.00K | $10.06M | -55085.00% |
| 2015-12-31 | $-8.93M | $27.00K | $0.00 | $1.00M | $7.95M | -33062.96% |
| 2015-09-30 | $-7.66M | $60.00K | $35.00K | $475.00K | $7.21M | -12768.33% |
| 2015-06-30 | $-5.43M | $63.00K | $40.00K | $250.00K | $5.21M | -8623.81% |
| 2015-03-31 | $-4.11M | $68.00K | $57.00K | $250.00K | $3.87M | -6038.24% |
| 2014-12-31 | $-2.40M | $61.00K | $57.00K | $0.00 | $2.40M | -3927.87% |
| 2014-09-30 | $-986.00K | $69.00K | $44.00K | $0.00 | $1.01M | -1428.99% |
| 2014-06-30 | $-577.00K | $249.00K | $162.00K | $0.00 | $664.00K | -231.73% |
| 2014-03-31 | $-547.00K | $280.00K | $157.00K | $0.00 | $670.00K | -195.36% |
| 2013-12-31 | $-793.00K | $368.00K | $226.00K | $0.00 | $935.00K | -215.49% |
| 2013-09-30 | $-1.30M | $546.00K | $265.00K | $0.00 | $1.18M | -238.10% |
| 2013-06-30 | $-2.51M | $483.00K | $174.00K | $0.00 | $2.42M | -519.46% |
| 2013-03-31 | $-3.46M | $429.00K | $162.00K | $0.00 | $3.33M | -807.69% |
| 2012-12-31 | $-3.51M | $342.00K | $94.00K | $0.00 | $3.36M | -1027.49% |
| 2012-09-30 | $-3.82M | $126.00K | $33.00K | $-32.00K | $3.53M | -3034.13% |
| 2012-06-30 | $-3.02M | $7.00K | $9.00K | $-32.00K | $2.63M | -43071.43% |
| 2012-03-31 | $-2.47M | $7.00K | $24.00K | (m) | $2.03M | -35228.57% |
| 2011-12-31 | $-3.93M | $26.00K | $48.00K | $17.00K | $3.47M | -15107.69% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-2.50M | $11.00K | $65.00K | $179.00K | $2.26M | -22700.00% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |